Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vertex Pharmaceuticals (NQ: VRTX ) 474.77 +4.49 (+0.95%) Streaming Delayed Price Updated: 11:34 AM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vertex Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 49 50 Next > Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)? June 12, 2024 Why NASDAQ:VRTX Stands Out as a Quality Stock. Via Chartmill 2 Healthcare Stocks to Buy Hand Over Fist in June June 12, 2024 They both have pretty impressive pasts, and their prospects look just as bright. Via The Motley Fool Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday June 11, 2024 Via Benzinga Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO June 10, 2024 Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services. Via Talk Markets Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought June 09, 2024 These companies could generate explosive growth over time. Via The Motley Fool $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today June 05, 2024 Via Benzinga This Is What Whales Are Betting On Vertex Pharmaceuticals June 03, 2024 Via Benzinga Analyst Expectations For Vertex Pharmaceuticals's Future May 31, 2024 Via Benzinga Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst June 07, 2024 Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety . Via Benzinga Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA® June 07, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Large Cap BIopharmaceuticals Overview June 03, 2024 As a defensive play healthcare is weighted at about 12% of the S&P 500. Via Talk Markets Topics Stocks Exposures US Equities 3 No-Brainer Stocks to Buy in June June 02, 2024 Now is the time to invest in these great stocks. Via The Motley Fool While growth is established for NASDAQ:VRTX, the stock's valuation remains reasonable. May 29, 2024 NASDAQ:VRTX is showing decent growth, but is still valued reasonably. Via Chartmill 2 Biotech Stocks to Buy in May May 25, 2024 You could buy these in any month, really. Via The Motley Fool Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity May 23, 2024 Via Benzinga 5 Top Stocks to Buy in June June 02, 2024 This medley of growth, value, and income stocks is poised to thrive long-term, even if the stock market sells off this summer. Via The Motley Fool S&P 500 Giants Lead Five Healthy Stocks Near Buy Points June 01, 2024 Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. Via Investor's Business Daily Topics Stocks Exposures US Equities A Very Bullish Reversal Produces A Huge Batch Of Actionable Stocks May 31, 2024 It is very hard to get excited about what I'm seeing in the stock market because things have not been the way I've wanted them to be. In this video, I want to show you something as we look at a monthly... Via Talk Markets Vertex Stock Recently Hit All-Time High, Leads 8 Top Performers New To IBD Stock Lists May 31, 2024 Vertex stock was one of a select group of eight that made it onto IBD top-stocks lists Friday. The big pharma is near its all-time high. Via Investor's Business Daily Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals? May 30, 2024 Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. Via The Motley Fool Should you consider NASDAQ:VRTX for quality investing? May 22, 2024 VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Exhibits Quality Stock Traits. Here's Why. Via Chartmill Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic May 28, 2024 Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function. Via Benzinga Got $500? 3 Pharma Stocks to Buy and Hold Forever May 26, 2024 These players might even beat the market when the conditions are right. Via The Motley Fool Is It Too Late to Buy Vertex Pharmaceuticals Stock? May 26, 2024 Shares of the growing biotech company have doubled in three years. Via The Motley Fool 3 High-Flying Stocks That Could Soar Even More May 25, 2024 The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals. Via The Motley Fool SLB, First Solar And 2 Other Stocks Insiders Are Selling May 23, 2024 Via Benzinga Walmart, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' May 23, 2024 Walmart Inc. reported a "really strong" quarter, with e-commerce sales surging 21%. Adjusted EPS was 60 cents. Via Benzinga The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now May 23, 2024 With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy. Via InvestorPlace Vertex to Participate in Upcoming June Investor Conferences May 22, 2024 From Vertex Pharmaceuticals Incorporated Via Business Wire Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating May 16, 2024 On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 ... 49 50 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.